vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and MAXLINEAR, INC (MXL). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $137.2M, roughly 1.0× MAXLINEAR, INC). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -32.9%, a 68.4% gap on every dollar of revenue. On growth, MAXLINEAR, INC posted the faster year-over-year revenue change (43.0% vs 18.4%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 22.1%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
MaxLinear, Inc. is an American electronic hardware company. Founded in 2003, it provides highly integrated radio-frequency (RF) analog and mixed-signal semiconductor products for broadband communications applications. It is a New York Stock Exchange-traded company.
ADMA vs MXL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $137.2M |
| Net Profit | $49.4M | $-45.1M |
| Gross Margin | 63.8% | 57.5% |
| Operating Margin | 45.1% | 30.0% |
| Net Margin | 35.5% | -32.9% |
| Revenue YoY | 18.4% | 43.0% |
| Net Profit YoY | -55.9% | -203.0% |
| EPS (diluted) | $0.20 | $-0.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $137.2M | ||
| Q4 25 | $139.2M | $136.4M | ||
| Q3 25 | $134.2M | $126.5M | ||
| Q2 25 | $122.0M | $108.8M | ||
| Q1 25 | $114.8M | $95.9M | ||
| Q4 24 | $117.5M | $92.2M | ||
| Q3 24 | $119.8M | $81.1M | ||
| Q2 24 | $107.2M | $92.0M |
| Q1 26 | — | $-45.1M | ||
| Q4 25 | $49.4M | $-14.9M | ||
| Q3 25 | $36.4M | $-45.5M | ||
| Q2 25 | $34.2M | $-26.6M | ||
| Q1 25 | $26.9M | $-49.7M | ||
| Q4 24 | $111.9M | $-57.8M | ||
| Q3 24 | $35.9M | $-75.8M | ||
| Q2 24 | $32.1M | $-39.3M |
| Q1 26 | — | 57.5% | ||
| Q4 25 | 63.8% | 57.6% | ||
| Q3 25 | 56.3% | 56.9% | ||
| Q2 25 | 55.1% | 56.5% | ||
| Q1 25 | 53.2% | 56.1% | ||
| Q4 24 | 53.9% | 55.6% | ||
| Q3 24 | 49.8% | 54.4% | ||
| Q2 24 | 53.6% | 54.6% |
| Q1 26 | — | 30.0% | ||
| Q4 25 | 45.1% | -10.9% | ||
| Q3 25 | 38.0% | -32.7% | ||
| Q2 25 | 35.1% | -22.6% | ||
| Q1 25 | 30.4% | -48.0% | ||
| Q4 24 | 32.6% | -44.7% | ||
| Q3 24 | 33.1% | -82.3% | ||
| Q2 24 | 36.6% | -44.4% |
| Q1 26 | — | -32.9% | ||
| Q4 25 | 35.5% | -10.9% | ||
| Q3 25 | 27.1% | -36.0% | ||
| Q2 25 | 28.1% | -24.4% | ||
| Q1 25 | 23.4% | -51.8% | ||
| Q4 24 | 95.2% | -62.8% | ||
| Q3 24 | 30.0% | -93.4% | ||
| Q2 24 | 29.9% | -42.7% |
| Q1 26 | — | $-0.52 | ||
| Q4 25 | $0.20 | $-0.17 | ||
| Q3 25 | $0.15 | $-0.52 | ||
| Q2 25 | $0.14 | $-0.31 | ||
| Q1 25 | $0.11 | $-0.58 | ||
| Q4 24 | $0.45 | $-0.68 | ||
| Q3 24 | $0.15 | $-0.90 | ||
| Q2 24 | $0.13 | $-0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $61.1M |
| Total DebtLower is stronger | $72.1M | $123.8M |
| Stockholders' EquityBook value | $477.3M | $454.2M |
| Total Assets | $624.2M | $771.3M |
| Debt / EquityLower = less leverage | 0.15× | 0.27× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $61.1M | ||
| Q4 25 | $87.6M | $72.8M | ||
| Q3 25 | $61.4M | $111.9M | ||
| Q2 25 | $90.3M | $108.6M | ||
| Q1 25 | $71.6M | $102.8M | ||
| Q4 24 | $103.1M | $118.6M | ||
| Q3 24 | $86.7M | $148.5M | ||
| Q2 24 | $88.2M | $185.1M |
| Q1 26 | — | $123.8M | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $454.2M | ||
| Q4 25 | $477.3M | $451.9M | ||
| Q3 25 | $431.2M | $464.7M | ||
| Q2 25 | $398.3M | $488.3M | ||
| Q1 25 | $373.4M | $493.2M | ||
| Q4 24 | $349.0M | $516.3M | ||
| Q3 24 | $231.9M | $556.9M | ||
| Q2 24 | $188.3M | $617.3M |
| Q1 26 | — | $771.3M | ||
| Q4 25 | $624.2M | $796.4M | ||
| Q3 25 | $568.7M | $808.1M | ||
| Q2 25 | $558.4M | $863.7M | ||
| Q1 25 | $510.6M | $855.3M | ||
| Q4 24 | $488.7M | $864.6M | ||
| Q3 24 | $390.6M | $895.3M | ||
| Q2 24 | $376.4M | $973.2M |
| Q1 26 | — | 0.27× | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $10.4M | ||
| Q3 25 | $13.3M | $10.1M | ||
| Q2 25 | $21.1M | $10.5M | ||
| Q1 25 | $-19.7M | $-11.4M | ||
| Q4 24 | $50.2M | $-27.8M | ||
| Q3 24 | $25.0M | $-30.7M | ||
| Q2 24 | $45.6M | $-2.7M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $6.7M | ||
| Q3 25 | $-1.1M | $4.4M | ||
| Q2 25 | $18.7M | $9.3M | ||
| Q1 25 | $-24.4M | $-13.4M | ||
| Q4 24 | $47.5M | $-30.0M | ||
| Q3 24 | $24.0M | $-34.9M | ||
| Q2 24 | $43.6M | $-5.7M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 4.9% | ||
| Q3 25 | -0.8% | 3.5% | ||
| Q2 25 | 15.3% | 8.6% | ||
| Q1 25 | -21.2% | -14.0% | ||
| Q4 24 | 40.4% | -32.6% | ||
| Q3 24 | 20.0% | -43.0% | ||
| Q2 24 | 40.7% | -6.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 2.7% | ||
| Q3 25 | 10.7% | 4.5% | ||
| Q2 25 | 2.0% | 1.1% | ||
| Q1 25 | 4.1% | 2.1% | ||
| Q4 24 | 2.3% | 2.4% | ||
| Q3 24 | 0.9% | 5.1% | ||
| Q2 24 | 1.9% | 3.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
MXL
Segment breakdown not available.
